{"publication_id":"104ef0f2-3c97-42e2-8507-9b6ddf7ebf49","screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that glynac should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Across 16 curated reference papers, the evidence base for glynac shows a context-dependent profile. Positive signals appear in: deficiency prevalence. Null findings dominate: deficiency prevalence, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The glynac anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","Additional corpus sources included animal/preclinical evidence; - Severity 4 disagreement: Wang 2026 vs Sekhar 2022; Wang 2026 (unclear) vs Sekhar 2022 (mixed) on dosing pharmacokinetics"]}